Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 7 of 93.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2017-002930-22 Sponsor Protocol Number: IOM-050371 Start Date*: 2018-02-14
    Sponsor Name:iOMEDICO AG
    Full Title: A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in patients with metastatic hormone receptor-positive HER2-negative breast cancer receiving ...
    Medical condition: The study will include adult women with HR-positive, HER2-negative advanced breast cancer with visceral metastases, who received no prior therapy for advanced disease.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001949-34 Sponsor Protocol Number: E7389-G000-305 Start Date*: 2006-10-02
    Sponsor Name:Eisai Limited
    Full Title: A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician’s Choice’ in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously T...
    Medical condition: Locally recurrent or metastatic breast cancer after failure of multiple prior chemotherapy regimens
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (Completed) CZ (Completed) FR (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004100-35 Sponsor Protocol Number: GBG102-SASCIA Start Date*: 2020-10-09
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treat...
    Medical condition: HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) AT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017671-22 Sponsor Protocol Number: E7389-G000-398 Start Date*: 2010-07-15
    Sponsor Name:Eisai Limited
    Full Title: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies
    Medical condition: Advanced and/or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006198 Breast cancer recurrent LLT
    12.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002714-72 Sponsor Protocol Number: GBG89 Start Date*: 2016-03-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. (GeparNuevo)
    Medical condition: Patients with triple negative, early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002080-25 Sponsor Protocol Number: NBG-19-01 Start Date*: 2019-06-26
    Sponsor Name:Skåne University Hospital
    Full Title: A TRANSLATIONAL RANDOMIZED PHASE III STUDY EXPLORING THE EFFECT OF THE ADDITION OF CAPECITABINE TO CARBOPLATINUM BASED CHEMOTHERAPY IN EARLY “TRIPLE NEGATIVE” BREAST CANCER.
    Medical condition: Early triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004848-23 Sponsor Protocol Number: 89/2006/O/Sper Start Date*: 2006-09-12
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Sequential Oral Therapy (SOT trial) in elderly patients with metastatic breast cancer: a phase IV randomized trial
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007057-12 Sponsor Protocol Number: ML21846 Start Date*: 2009-04-06
    Sponsor Name:ROCHE
    Full Title: A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on...
    Medical condition: Metastatic breast cancer, HER2-negative patients who have not received prior chemotherapy for mBC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006285 LLT
    9.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004220-34 Sponsor Protocol Number: TNPET01 Start Date*: 2012-01-19
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility...
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-006381-29 Sponsor Protocol Number: EXPRESSION Start Date*: 2009-11-12
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene...
    Medical condition: Eligible will be only females between 18 - 70 years of age, suffering from histologically confirmed primary breast cancer, nodal status positive or negative, phase cT2, cT3, or cT4 including inflam...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000418-31 Sponsor Protocol Number: IKP275 Start Date*: 2019-04-01
    Sponsor Name:Robert Bosch Gesellschaft für medizinische Forschung mbH
    Full Title: GENOTYPE AND PHENOTYPE GUIDED SUPPLEMENTATION OF TAMOXIFEN STANDARD THERAPY WITH ENDOXIFEN IN BREAST CANCER PATIENTS.
    Medical condition: Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001889-14 Sponsor Protocol Number: Bubble2012 Start Date*: 2012-10-15
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: MicroBubble detection and Ultrasound guided Biopsy of axillary Lymph nodes in patients with Early breast cancer.
    Medical condition: Diagnosis of lymph node metastases in patients with newly diagnosed breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021587-15 Sponsor Protocol Number: ICORG10-04NSABP-B46I Start Date*: 2010-09-08
    Sponsor Name:ICORG
    Full Title: A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
    Medical condition: Adjuvant Breast Cancer: Node positive or high risk node negative and HER 2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003992-35 Sponsor Protocol Number: MREC02/8/71 Start Date*: 2009-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.
    Medical condition: Ductal carcinoma in situ
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10013806 Ductal carcinoma in situ LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001545-42 Sponsor Protocol Number: B9E-IT-S376 Start Date*: 2005-07-13
    Sponsor Name:ELI LILLY
    Full Title: A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules
    Medical condition: Metatstatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016062-82 Sponsor Protocol Number: ML22373 Start Date*: 2009-11-23
    Sponsor Name:SOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP
    Full Title: Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancer
    Medical condition: Metastatic or locally recurrent HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10055113 Breast cancer metastatic LLT
    12.0 10006198 Breast cancer recurrent LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001456-36 Sponsor Protocol Number: EGF100151 Start Date*: 2004-09-06
    Sponsor Name:GLAXO SMITHKLINE
    Full Title: A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer.
    Medical condition: Solid tumor treatment
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006279 Breast neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004989-23 Sponsor Protocol Number: G200901 Start Date*: 2015-08-20
    Sponsor Name:GTx, Inc.
    Full Title: A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
    Medical condition: Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006168-71 Sponsor Protocol Number: SF2- Gem/tax Start Date*: 2006-02-16
    Sponsor Name:A.S.L. 2
    Full Title: Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer
    Medical condition: oncological patients only
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005683-87 Sponsor Protocol Number: VNBCAPTAX Start Date*: 2006-02-22
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES
    Medical condition: METASTATIC BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    6.1 10055113 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 13:26:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA